New vaccine hope for kids with deadly brain tumors
NCT ID NCT04911621
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a special vaccine made from the child's own immune cells (dendritic cells) to fight aggressive brain tumors like high-grade glioma and DIPG. Ten children received the vaccine alongside standard treatments. The goal was to see if the vaccine was safe, possible to make, and could boost the immune system to slow tumor growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
10 people
The number who actually took part.
- Started
-
Sep 2021
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 months to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of * High grade glioma (WHO grade III or IV), histologically verified * Diffuse Intrinsic Pontine Glioma, verified by radiologic criteria (magnetic resonance imaging (MRI)) or by histology. A biopsy is not required but recommended. * Aged ≥ 12 months and \< 18 years at the time of signing the informed consent * Body weight ≥ 10 kg * Lansky score (for patients \< 16 years) or Karnofsky score (for patients ≥ 16 years) of ≥ 50 * Reasonable life expectancy ≥ 8 weeks, as estimated by the treating physician * Adequate hematological blood values and sufficient recovery from treatment-related toxicities (\> grade 1) following previous anti-glioma treatments, as judged by the treating physician * Written informed consent of parents or legal guardian. Written informed consent of patients aged 12 years or older (written informed consent of patients younger than 12 years is optional). * Willing and able to comply with the protocol, as judged by the treating physician * Female patients of child bearing potential must have a negative serum or urine pregnancy test at the time of screening. Female patients of child bearing potential and male patients must agree to use effective contraception before, during and for at least hundred days after the last study treatment administration. Female subjects who are breastfeeding should discontinue nursing prior to the first dose of study treatment and until at least hundred days after the last study treatment administration. Exclusion Criteria: * Use of any investigational agents ≤ 4 weeks before the planned day of leukapheresis. * Concomitant malignancy or history of another malignancy (unless the Investigator rationalizes otherwise) * Known concomitant presence of any active immunosuppressive disease (e.g. HIV) or any active autoimmune condition, except for vitiligo * Any pre-existing contra-indication for contrast-enhanced MRI * Pregnant or breastfeeding * Any other condition, either physical or psychological, or reasonable suspicion thereof on clinical or special investigation, which contraindicates the use of the vaccine, or may negatively affect patient compliance, or may place the patient at higher risk of potential treatment complications
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diffuse intrinsic pontine glioma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Unitversity Hospital Antwerp
Edegem, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves open the brain to Cancer-Fighting cells?
- Brain surgery safety: live signal monitoring may shield speech, movement, and sight
- Can trained immune cells outsmart brain tumors?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a 7-Week brain tumor treatment beat the standard 10-Week plan?